Opportunity types being sought:
Takeda Pharmaceutical are launching an open innovation initiative inviting researchers to submit their proposals addressing emerging technological platforms related to oncology, rare genetic or haematological disease, or medicinal chemistry. One‑year projects will be funded up to JPY 5,000,000 or equivalent amount, including indirect costs.
REF#6 Translational research platforms for immuno-oncology. Specifically: (i) translationally-relevant humanised animal models and/or in vitro/ex vivo tumour organoid systems reflecting human immune components, and (ii) novel biomarker discovery approaches/platforms for immuno-oncology.
REF#7 Imaging agents of lysosomal health. Approaches enabling visualisation of lysosomal activity in vivo are envisioned. Small molecules that can be labelled for PET imaging are of particular interest.
REF#8 Novel chemistry‑driven technologies for nucleic acid drug development. Specifically:
REF#9 Chemistry-driven novel technologies, methods or approaches to accelerate drug discovery process. Specifically:
Only submissions from Australia, New Zealand, Singapore, South Korea and Taiwan will be eligible for this campaign.
To view more details on each area of interest seeking proposals for funding, download a proposal template here. For terms and conditions, click here. To submit your proposal, please visit our website at discover.in-part.com, register, and submit your proposal under the appropriate Discover campaign.